Lung Diseases, Interstitial
|
0.050 |
Biomarker
|
group |
BEFREE |
Recently, a number of myositis-specific and -associated autoantibodies (MSAs/MAAs) have been identified and well characterized, and commercial assays for their detection have become available.<b>Areas covered</b>: There is accumulating evidence showing the utility of MSAs/MAAs in diagnosis of DM and in predicting clinical courses and outcomes in patients with DM as convenient biomarkers, i.e. an association of ILD with anti-ARS, anti-MDA5 and anti-SAE; and malignancy with anti-TIF1-γ, anti-NXP2, and anti-SAE in adults.
|
31779485 |
2020 |
Lung Diseases, Interstitial
|
0.050 |
Biomarker
|
group |
BEFREE |
Propensity score-matched analysis demonstrated that first-line PSL + CNI therapy for patients with ARS-PM/DM-ILD significantly improved the PFS compared with PSL monotherapy, although there was no significant difference regarding longterm survival.
|
30647164 |
2019 |
Lung Diseases, Interstitial
|
0.050 |
Biomarker
|
group |
BEFREE |
Patients with anti-aminoacyl-tRNA synthetase antibody (ARS-Ab) and anti-melanoma differentiation-associated gene 5 (MDA5)-Ab often have interstitial lung disease (ILD).
|
31631384 |
2019 |
Lung Diseases, Interstitial
|
0.050 |
GeneticVariation
|
group |
BEFREE |
Among the MMPs analysed, MMP-7 serum levels in the ARS-ILD group were significantly higher compared with those in any of the other groups of PM/DM patients or in healthy controls.
|
30851107 |
2019 |
Lung Diseases, Interstitial
|
0.050 |
Biomarker
|
group |
BEFREE |
Although we reported the clinical characteristics of interstitial lung disease with anti-ARS antibodies (ARS-ILD) with and without PM/DM, the long-term prognosis of ARS-ILD remains undetermined.
|
28461123 |
2017 |
Meleda Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
We report here a Tunisian family with three siblings presenting with recessive transgressive PPK closely resembling the MDM phenotype that excludes linkage to the ARS gene.
|
16865292 |
2006 |
Meleda Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Mal de Meleda (MDM) is a rare form of recessive transgressive palmoplantar erythrokeratoderma for which mutations in the ARS gene have been identified recently.
|
15909066 |
2005 |
Meleda Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
These findings support the notion that mutations in the ARS gene are pathogenic in mal de Meleda.
|
12535203 |
2003 |
Meleda Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
The results suggest that the ARS gene is likely to be responsible for MDM in the eight Tunisian families.
|
14674887 |
2003 |
Meleda Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Here we report a patient suffering from Mal de Meleda not associated with ARS mutations.
|
11872406 |
2002 |
Dermatomyositis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Recently, a number of myositis-specific and -associated autoantibodies (MSAs/MAAs) have been identified and well characterized, and commercial assays for their detection have become available.<b>Areas covered</b>: There is accumulating evidence showing the utility of MSAs/MAAs in diagnosis of DM and in predicting clinical courses and outcomes in patients with DM as convenient biomarkers, i.e. an association of ILD with anti-ARS, anti-MDA5 and anti-SAE; and malignancy with anti-TIF1-γ, anti-NXP2, and anti-SAE in adults.
|
31779485 |
2020 |
Adult type dermatomyositis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Recently, a number of myositis-specific and -associated autoantibodies (MSAs/MAAs) have been identified and well characterized, and commercial assays for their detection have become available.<b>Areas covered</b>: There is accumulating evidence showing the utility of MSAs/MAAs in diagnosis of DM and in predicting clinical courses and outcomes in patients with DM as convenient biomarkers, i.e. an association of ILD with anti-ARS, anti-MDA5 and anti-SAE; and malignancy with anti-TIF1-γ, anti-NXP2, and anti-SAE in adults.
|
31779485 |
2020 |
Thrombocytopenia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The hemorrhagic syndrome associated with the ARS in rabbits is characterized by thrombocytopenia and hemostasis dysfunction, which appear to underlie the development of multiorgan dysfunction following TBI to rabbits.
|
31526203 |
2019 |
Thrombocytopenia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Ionizing radiation combined with trauma tissue injury (combined injury, CI) results in greater mortality and H-ARS than radiation alone (radiation injury, RI), which includes thrombocytopenia.
|
28408792 |
2017 |
Charcot-Marie-Tooth Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Mutations in several aminoacyl-tRNA synthetase (ARS) genes have been implicated in inherited CMT disease.
|
27008886 |
2016 |
Malignant neoplasm of breast
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
These findings indicate that genetic variants in core ARSs genes may modify the individual susceptibility to breast cancer in Chinese population.
|
24510587 |
2015 |
Dermatomyositis
|
0.020 |
Biomarker
|
disease |
BEFREE |
The significantly lower frequency of anti-ARS antibodies and significantly higher frequency of anti-MDA5 antibodies in the Chinese patients were observed in the classic DM subset (14.7 % [10/68] versus 46.4 % [26/56], respectively, P < 0.001, and 45.6 % [31/68] versus 5.4 % [3/56], respectively, P < 0.001) and CADM subset (8.0 % [2/25] versus 28.8 % [15/52], respectively, P = 0.04, and 88.0 % [22/25] versus 44.2 % [23/52], respectively, P = 0.0002), but not in the PM subset.
|
25903820 |
2015 |
Adult type dermatomyositis
|
0.020 |
Biomarker
|
disease |
BEFREE |
The significantly lower frequency of anti-ARS antibodies and significantly higher frequency of anti-MDA5 antibodies in the Chinese patients were observed in the classic DM subset (14.7 % [10/68] versus 46.4 % [26/56], respectively, P < 0.001, and 45.6 % [31/68] versus 5.4 % [3/56], respectively, P < 0.001) and CADM subset (8.0 % [2/25] versus 28.8 % [15/52], respectively, P = 0.04, and 88.0 % [22/25] versus 44.2 % [23/52], respectively, P = 0.0002), but not in the PM subset.
|
25903820 |
2015 |
Breast Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
These findings indicate that genetic variants in core ARSs genes may modify the individual susceptibility to breast cancer in Chinese population.
|
24510587 |
2015 |
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Interestingly, mRNA expression of steroid sulfatase STS, but not of arylsulfatases ARS-A and ARS-B, was significantly higher (p<0.0017) in non-malignant specimens than in tumor tissue samples, which might explain the higher resveratrol-3-O-sulfate concentrations in breast cancer specimens.
|
19747768 |
2010 |
Charcot-Marie-Tooth Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Based on these data, KARS becomes the fourth ARS gene associated with CMT disease, indicating that this family of enzymes is specifically critical for axon function.
|
20920668 |
2010 |
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Interestingly, mRNA expression of steroid sulfatase STS, but not of arylsulfatases ARS-A and ARS-B, was significantly higher (p<0.0017) in non-malignant specimens than in tumor tissue samples, which might explain the higher resveratrol-3-O-sulfate concentrations in breast cancer specimens.
|
19747768 |
2010 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Recently, a number of myositis-specific and -associated autoantibodies (MSAs/MAAs) have been identified and well characterized, and commercial assays for their detection have become available.<b>Areas covered</b>: There is accumulating evidence showing the utility of MSAs/MAAs in diagnosis of DM and in predicting clinical courses and outcomes in patients with DM as convenient biomarkers, i.e. an association of ILD with anti-ARS, anti-MDA5 and anti-SAE; and malignancy with anti-TIF1-γ, anti-NXP2, and anti-SAE in adults.
|
31779485 |
2020 |
Myositis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recently, a number of myositis-specific and -associated autoantibodies (MSAs/MAAs) have been identified and well characterized, and commercial assays for their detection have become available.<b>Areas covered</b>: There is accumulating evidence showing the utility of MSAs/MAAs in diagnosis of DM and in predicting clinical courses and outcomes in patients with DM as convenient biomarkers, i.e. an association of ILD with anti-ARS, anti-MDA5 and anti-SAE; and malignancy with anti-TIF1-γ, anti-NXP2, and anti-SAE in adults.
|
31779485 |
2020 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Recently, a number of myositis-specific and -associated autoantibodies (MSAs/MAAs) have been identified and well characterized, and commercial assays for their detection have become available.<b>Areas covered</b>: There is accumulating evidence showing the utility of MSAs/MAAs in diagnosis of DM and in predicting clinical courses and outcomes in patients with DM as convenient biomarkers, i.e. an association of ILD with anti-ARS, anti-MDA5 and anti-SAE; and malignancy with anti-TIF1-γ, anti-NXP2, and anti-SAE in adults.
|
31779485 |
2020 |